Compare AYTU & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | ESLA |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 32.0M |
| IPO Year | 2015 | 2021 |
| Metric | AYTU | ESLA |
|---|---|---|
| Price | $2.17 | $0.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.33 | $8.00 |
| AVG Volume (30 Days) | ★ 41.7K | 38.0K |
| Earning Date | 05-13-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.67 | $0.46 |
| 52 Week High | $3.07 | $3.15 |
| Indicator | AYTU | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 24.79 |
| Support Level | $2.21 | N/A |
| Resistance Level | $2.35 | $0.85 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 67.35 | 0.21 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.